Key result
Routine TTE and outpatient monitoring show wide, inconsistent diagnostic yield in ED syncope.
Why the study?
Syncope frequently prompts extensive emergency department testing, but the diagnostic utility of troponin, BNP, TTE, and outpatient cardiac monitoring remains unclear.
Does TTE, cardiac biomarkers (troponin, BNP), or outpatient arrhythmia monitoring improve outcomes within 30 days in ED patients with syncope compared with no testing?
Systematic Review
Does TTE, cardiac biomarkers (troponin, BNP), or outpatient arrhythmia monitoring improve outcomes within 30 days in ED patients with syncope compared with no testing?
Cardiac biomarkers, TTE, and outpatient monitoring show substantial variability in diagnostic accuracy and yield for ED syncope patients, and cannot be recommended for routine use in isolation.
Answers are grounded in this paper and cite their sources.
Variable diagnostic performance precludes routine BNP, troponin, TTE, or monitoring in ED syncope; challenges broad use and leaves selective strategies open.
BACKGROUND: Syncope places a significant burden on emergency departments (EDs), often prompting extensive testing to exclude life-threatening conditions. However, the diagnostic utility of troponin, B-type natriuretic peptide (BNP), transthoracic echocardiography (TTE), and outpatient cardiac monitoring remains unclear. METHODS: This systematic review assessed the diagnostic accuracy of these tests in adults presenting with syncope. The research question was: In ED patients with syncope, does TTE, cardiac biomarkers (troponin, BNP), or outpatient arrhythmia monitoring, compared with no testing, improve outcomes within 30 days? Primary outcomes included adverse events (death, arrhythmias, structural/ischemic heart disease, and select non-cardiac causes such as pulmonary embolism or aortic dissection) for biomarkers and diagnostic yield for TTE and monitoring. Sensitivity, specificity, and likelihood ratios (LR+ and LR-) were calculated for biomarkers, while diagnostic yield with 95% CI was reported for TTE and monitoring. Risk of bias was assessed using JBI and QUADAS-2. RESULTS: > 90%) precluded meta-analysis. For BNP, LR+ ranged 1.4-47 and LR- 0.06-0.4; for troponin, LR+ 1.9-11.2 and LR- 0.2-0.9. TTE diagnostic yield was 0%-29% overall and 8%-28% in high-risk groups. Outpatient monitoring yielded 1%-59% overall and 12%-42% in high-risk patients. CONCLUSION: In ED patients with syncope, the diagnostic accuracy and yield of cardiac biomarkers, TTE, and outpatient monitoring show substantial variability, largely due to differences in patient populations, outcome measures, and study methodologies. Based on the existing evidence, these modalities in isolation cannot be recommended for routine use in syncope evaluation. Among these tests, the diagnostic yield of TTE and outpatient monitoring is greater in patients with cardiac risk factors and could potentially contribute to a more accurate diagnosis.
No takes yet. Share an insight, caveat, or question.
Benabbas et al. (2025) conducted a systematic review in Syncope. Cardiac biomarkers, transthoracic echocardiography (TTE), and outpatient cardiac monitoring vs. no testing was evaluated on Adverse events for biomarkers and diagnostic yield for TTE and monitoring within 30 days. In ED patients with syncope, diagnostic yield varied widely for TTE and outpatient monitoring, indicating these modalities cannot be recommended for routine isolated use.
Synapse has enriched 10 related papers. Consider them for comparative context: